179 related articles for article (PubMed ID: 32427904)
1. LHRH-Conjugated Drugs as Targeted Therapeutic Agents for the Specific Targeting and Localized Treatment of Triple Negative Breast Cancer.
Obayemi JD; Salifu AA; Eluu SC; Uzonwanne VO; Jusu SM; Nwazojie CC; Onyekanne CE; Ojelabi O; Payne L; Moore CM; King JA; Soboyejo WO
Sci Rep; 2020 May; 10(1):8212. PubMed ID: 32427904
[TBL] [Abstract][Full Text] [Related]
2. In-vivo studies of targeted and localized cancer drug release from microporous poly-di-methyl-siloxane (PDMS) devices for the treatment of triple negative breast cancer.
Eluu SC; Obayemi JD; Salifu AA; Yiporo D; Oko AO; Aina T; Oparah JC; Ezeala CC; Etinosa PO; Ugwu CM; Esimone CO; Soboyejo WO
Sci Rep; 2024 Jan; 14(1):31. PubMed ID: 38167999
[TBL] [Abstract][Full Text] [Related]
3. Drug-encapsulated blend of PLGA-PEG microspheres: in vitro and in vivo study of the effects of localized/targeted drug delivery on the treatment of triple-negative breast cancer.
Jusu SM; Obayemi JD; Salifu AA; Nwazojie CC; Uzonwanne V; Odusanya OS; Soboyejo WO
Sci Rep; 2020 Aug; 10(1):14188. PubMed ID: 32843673
[TBL] [Abstract][Full Text] [Related]
4. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB
BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881
[TBL] [Abstract][Full Text] [Related]
5. Enhanced cellular uptake of LHRH-conjugated PEG-coated magnetite nanoparticles for specific targeting of triple negative breast cancer cells.
Hu J; Obayemi JD; Malatesta K; Košmrlj A; Soboyejo WO
Mater Sci Eng C Mater Biol Appl; 2018 Jul; 88():32-45. PubMed ID: 29636136
[TBL] [Abstract][Full Text] [Related]
6. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.
Föst C; Duwe F; Hellriegel M; Schweyer S; Emons G; Gründker C
Oncol Rep; 2011 May; 25(5):1481-7. PubMed ID: 21331448
[TBL] [Abstract][Full Text] [Related]
7. LHRH-Targeted Redox-Responsive Crosslinked Micelles Impart Selective Drug Delivery and Effective Chemotherapy in Triple-Negative Breast Cancer.
Xiao K; Liu Q; Suby N; Xiao W; Agrawal R; Vu M; Zhang H; Luo Y; Li Y; Lam KS
Adv Healthc Mater; 2021 Feb; 10(3):e2001196. PubMed ID: 33200571
[TBL] [Abstract][Full Text] [Related]
8. Targeted drug-loaded PLGA-PCL microspheres for specific and localized treatment of triple negative breast cancer.
Nwazojie CC; Obayemi JD; Salifu AA; Borbor-Sawyer SM; Uzonwanne VO; Onyekanne CE; Akpan UM; Onwudiwe KC; Oparah JC; Odusanya OS; Soboyejo WO
J Mater Sci Mater Med; 2023 Aug; 34(8):41. PubMed ID: 37530973
[TBL] [Abstract][Full Text] [Related]
9. Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition.
Buchholz S; Seitz S; Schally AV; Engel JB; Rick FG; Szalontay L; Hohla F; Krishan A; Papadia A; Gaiser T; Brockhoff G; Ortmann O; Diedrich K; Köster F
Int J Oncol; 2009 Oct; 35(4):789-96. PubMed ID: 19724914
[TBL] [Abstract][Full Text] [Related]
10. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide.
Dharap SS; Wang Y; Chandna P; Khandare JJ; Qiu B; Gunaseelan S; Sinko PJ; Stein S; Farmanfarmaian A; Minko T
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12962-7. PubMed ID: 16123131
[TBL] [Abstract][Full Text] [Related]
11. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
Engel J; Emons G; Pinski J; Schally AV
Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
[TBL] [Abstract][Full Text] [Related]
12. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
13. Adhesion of LHRH/EphA2 to human Triple Negative Breast Cancer tissues.
Ezenwafor TC; Uzonwanne VO; Madukwe JUA; Amin SM; Anye VC; Obayemi JD; Odusanya OS; Soboyejo WO
J Mech Behav Biomed Mater; 2022 Dec; 136():105461. PubMed ID: 36195050
[TBL] [Abstract][Full Text] [Related]
14. Application of luteinizing hormone-releasing hormone-ferrosoferric oxide nanoparticles in targeted imaging of breast tumors.
Nian D; Shi P; Sun J; Ren L; Hao X; Han J
J Int Med Res; 2019 Apr; 47(4):1749-1757. PubMed ID: 30880516
[TBL] [Abstract][Full Text] [Related]
15. Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
Engel JB; Keller G; Schally AV; Nagy A; Chism DD; Halmos G
Fertil Steril; 2005 Apr; 83 Suppl 1():1125-33. PubMed ID: 15831285
[TBL] [Abstract][Full Text] [Related]
16. Pt-Mal-LHRH, a Newly Synthesized Compound Attenuating Breast Cancer Tumor Growth and Metastasis by Targeting Overexpression of the LHRH Receptor.
Calderon LE; Keeling JK; Rollins J; Black CA; Collins K; Arnold N; Vance DE; Ndinguri MW
Bioconjug Chem; 2017 Feb; 28(2):461-470. PubMed ID: 27997127
[TBL] [Abstract][Full Text] [Related]
17. Adhesion of ligand-conjugated biosynthesized magnetite nanoparticles to triple negative breast cancer cells.
Obayemi JD; Hu J; Uzonwanne VO; Odusanya OS; Malatesta K; Anuku N; Soboyejo WO
J Mech Behav Biomed Mater; 2017 Apr; 68():276-286. PubMed ID: 28226310
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of aerobic glycolysis enhances the anti-tumor efficacy of Zoptarelin Doxorubicin in triple-negative breast cancer cells.
Gründker C; Wokoun U; Hellriegel M; Emons G
J Obstet Gynaecol Res; 2019 Jul; 45(7):1334-1342. PubMed ID: 31016845
[TBL] [Abstract][Full Text] [Related]
19. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152.
Emons G; Sindermann H; Engel J; Schally AV; Gründker C
Neuroendocrinology; 2009; 90(1):15-8. PubMed ID: 19521066
[TBL] [Abstract][Full Text] [Related]
20. Targeted Tubulysin B Hydrazide Conjugate for the Treatment of Luteinizing Hormone-Releasing Hormone Receptor-Positive Cancers.
Roy J; Kaake M; Srinivasarao M; Low PS
Bioconjug Chem; 2018 Jul; 29(7):2208-2214. PubMed ID: 29851465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
